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Introduction. Two main forms of acute leukemia – acute lymphoblastic leukemia (ALL) and 
acute myeloid leukemia (AML) occupies approximately 30% among of the pediatric 
malignancies. Average incidence of leukemia’s in Ukraine in 2016 is 3.77 per 100 000 child 
population (in Sumy region – 2.87). Based on the results of the last event-free survival analysis 
of ALL children (n = 763) who were treated at the centers of the Ukrainian Cooperative Group 
according to the protocols ALL IC BFM 2002 and ALL IC BFM 2009, the overall recovery rate 
was 71%. 
Aim. Overview the novel therapeutic strategies for pediatric patients with leukemia to reducing 
long-term negative impact of therapy, decrease frequency of refractive to current therapy cases 
and increase overall recovery rate to 80% for patients with ALL. 
Results. Selective delivery of anti-cancer agents to cancer cells without harming the healthy 
cells is a major goal of novel nanoparticle-based pediatric leukemia therapy. Some studies are 
show that lipoprotein receptors (especially the HDL receptor) are highly active on the surface of 
malignant leukemic cells, that’s why may be used as conduits for the delivery of anti-cancer 
agents [1]. Liposomal vincristine sulfate was the first nanoformulation to get approval by the 
FDA to treat Ph+ ALL in adults [2]. Children tolerate 2.25 mg/m2/dose of weekly liposomal 
vincristine sulfate with evidence for clinical activity without dose‐limiting neurotoxicity [3]. 
Liposomal doxorubicin and pegylated (polyethylene glycol coated) liposome-encapsulated 
doxorubicin has an impressive safety profile, particularly regarding acute cardiac toxicity, in 
childhood leukemia [4]. Pegylated formula of L-asparaginase decreases immunogenicity, 
increases circulating half-life and can be used in patients with hypersensitive to un-pegylated 
products [5]. 
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